Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are attaching herewith the Annual Secretarial Compliance Report for the Financial ....
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Glenmark Pharmaceuticals has submitted its Annual Secretarial Compliance Report for FY 2025-26, certified by Rauthan & Associates Company Secretaries LLP. The report confirms full compliance with all SEBI regulations including SEBI LODR, ICDR, SAST, SBEB, PIT, and Depositories Regulations. The company maintained a functional website, obtained prior Audit Committee approval for all related party transactions, complied with Regulation 3(5) and 3(6) of PIT including Structured Digital Database maintenance, and conducted timely performance evaluations of the Board, Independent Directors, and Committees. No deviations, violations, or penalties were reported. No actions were taken against the company by SEBI or stock exchanges during the review period.
This is a positive compliance filing for Glenmark Pharmaceuticals shareholders. The clean bill of health from an independent secretarial auditor confirms the company maintained proper governance standards and regulatory compliance throughout FY 2025-26, which supports investor confidence in the company's governance practices.